A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

NCT04026412 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

925

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer (NSCLC)

Interventions

BIOLOGICAL: nivolumab
BIOLOGICAL: ipilimumab
BIOLOGICAL: durvalumab

Sponsor

Bristol-Myers Squibb